GlassScriptPhysician profile
Robert D Nichols
NPI 1063568673
$7,959.55
in general payments reported to CMS, 2019-2025
55 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $564 · 2021: $1,335 · 2022: $1,411 · 2023: $1,431 · 2024: $1,095 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,041.02 | 2021-2025 | |
| Novo Nordisk INC | $1,003.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $878.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $650.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $591.59 | 2019-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $336.93 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.29 | 2019-2025 | Jardiance, Stiolto Respimat |
| Pfizer INC. | $257.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $192.77 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $179.50 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $170.10 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $164.44 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Glaxosmithkline, LLC. | $151.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.05 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $125.96 | 2023 | Quviviq |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.